(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 April 2010 (08.04.2010)

PCT

(10) International Publication Number
WO 2010/038901 A1

(51) International Patent Classification:

C07D 401/06 (2006.01)	*A61P 25/02* (2006.01)
A61K 31/4709 (2006.01)	*A61P 25/08* (2006.01)
A61P 1/14 (2006.01)	*A61P 25/18* (2006.01)
A61P 3/04 (2006.01)	*A61P 25/20* (2006.01)
A61P 3/06 (2006.01)	*A61P 25/22* (2006.01)
A61P 3/10 (2006.01)	*A61P 25/24* (2006.01)
A61P 9/10 (2006.01)	*A61P 25/28* (2006.01)
A61P 9/12 (2006.01)	*A61P 25/36* (2006.01)
A61P 15/10 (2006.01)	*A61P 43/00* (2006.01)
A61P 25/00 (2006.01)	*C07D 401/14* (2006.01)

(21) International Application Number:
PCT/JP2009/067441

(22) International Filing Date:
30 September 2009 (30.09.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2008-257072 2 October 2008 (02.10.2008) JP

(71) Applicant *(for all designated States except US)*: **TAISHO PHARMACEUTICAL CO., LTD.** [JP/JP]; 24-1, Takada 3-chome, Toshima-ku, Tokyo, 1708633 (JP).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KANUMA, Kosuke** [JP/JP]; c/o TAISHO PHARMACEUTICAL CO., LTD., 24-1, Takada 3-chome, Toshima-ku, Tokyo, 1708633 (JP). **MIYAKOSHI, Naoki** [JP/JP]; c/o TAISHO PHARMACEUTICAL CO., LTD., 24-1, Takada 3-chome, Toshima-ku, Tokyo, 1708633 (JP). **KAWAMURA, Madoka** [JP/JP]; c/o TAISHO PHARMACEUTICAL CO., LTD., 24-1, Takada 3-chome, Toshima-ku, Tokyo, 1708633 (JP). **SHIBATA, Tsuyoshi** [JP/JP]; c/o TAISHO PHARMACEUTICAL CO., LTD., 24-1, Takada 3-chome, Toshima-ku, Tokyo, 1708633 (JP).

(74) Agents: **ASAMURA, Kiyoshi** et al.; Room 331, New Ohtemachi Bldg., 2-1, Ohtemachi 2-chome, Chiyoda-ku, Tokyo 1000004 (JP).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(54) Title: 7-PIPERIDINOALKYL-3,4-DIHYDROQUINOLONE DERIVATIVE



(I)

(57) Abstract: To provide a novel compound, a pharmaceutically acceptable salt or a hydrate thereof useful for preventing or treating for depression, anxiety disorders (such as generalized anxiety disorder, posttraumatic stress disorder, panic disorder, obsessive-compulsive disorder or social anxiety disorder), attention deficit disorder, mania, manic-depressive illness, schizophrenia, mood disorders, stress, sleep disorders, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, cardiovascular diseases, hypertension, dyslipidemia, myocardial infarction, movement disorder (such as Parkinson's disease, epilepsy, convulsion or tremor), drug abuse, drug addiction or sexual dysfunction, based on a melanin-concentrating hormone receptor (MCH receptor) antagonistic action. SOLUTION A compound, a pharmaceutically acceptable salt or a hydrate thereof represented by the formula (I).

WO 2010/038901 A1